journal
MENU ▼
Read by QxMD icon Read
search

Multiple Sclerosis Journal—Experimental, Translational and Clinical

journal
https://www.readbyqxmd.com/read/30637116/the-fluent-study-design-investigating-immune-cell-subset-and-neurofilament-changes-in-patients-with-relapsing-multiple-sclerosis-treated-with-fingolimod
#1
Jeffrey A Cohen, Amit Bar-Or, Bruce A C Cree, Yang Mao-Draayer, May H Han, Barry Singer, Ann Jannu, Scott Kolodny, Xiangyi Meng, Ryan C Winger
Background: Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of patients with relapsing forms of multiple sclerosis (RMS). Fingolimod sequesters lymphocytes within lymphoid tissue thereby reducing the counts of circulating lymphocytes. However, fingolimod's effects on the innate and adaptive components of the immune system are incompletely understood. Objective: The FLUENT study will investigate temporal changes in circulating immune cell subsets in patients with RMS treated with fingolimod...
January 2019: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30627437/contactin-1-and-contactin-2-in-cerebrospinal-fluid-as-potential-biomarkers-for-axonal-domain-dysfunction-in-multiple-sclerosis
#2
Madhurima Chatterjee, Marleen Ja Koel-Simmelink, Inge Mw Verberk, Joep Killestein, Hugo Vrenken, Christian Enzinger, Stefan Ropele, Franz Fazekas, Michael Khalil, Charlotte E Teunissen
Background: Contactin-1 and contactin-2 are important for the maintenance of axonal integrity. Objective: To investigate the cerebrospinal fluid levels of contactin-1 and contactin-2 in multiple sclerosis patients and controls, and their potential use as prognostic markers for neurodegeneration. Methods: Cerebrospinal fluid contactin-1 and contactin-2 were measured in relapsing-remitting multiple sclerosis ( n =  41), secondary progressive multiple sclerosis ( n =  26) and primary progressive multiple sclerosis patients ( n =  13) and controls ( n =  18), and in a second cohort with clinically isolated syndrome patients ( n =  88, median clinical follow-up period of 2...
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30622727/a-case-of-autoimmune-myositis-after-treatment-with-alemtuzumab-for-multiple-sclerosis
#3
Patrick Aouad, Con Yiannikas, Suran L Fernando, John Parratt
Alemtuzumab is a high-efficacy disease-modifying therapy for the treatment of relapsing forms of multiple sclerosis and is associated with secondary autoimmune adverse events. We report a novel case of secondary autoimmune myositis that occurred seven months after the initial treatment cycle and achieved full recovery with oral corticosteroids. This particular form of myositis appears to be unique, and is likely to be a distinct entity from the other four types of immune-mediated myositis.
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30574342/a-real-world-comparison-of-relapse-rates-healthcare-costs-and-resource-use-among-patients-with-multiple-sclerosis-newly-initiating-subcutaneous-interferon-beta-1a-versus-oral-disease-modifying-drugs
#4
James D Bowen, Chris M Kozma, Megan M Grosso, Amy L Phillips
Background: Administrative-claims data enable comparative effectiveness assessment using large numbers of patients treated in real-world settings. Objective: To evaluate real-world relapses, healthcare costs and resource use in patients with MS newly initiating subcutaneous interferon beta-1a (sc IFNβ-1a) v. oral disease-modifying drugs (DMDs: dimethyl fumarate, fingolimod, teriflunomide). Methods: Patients from an administrative claims database (1 Jan 2012-31 Dec 2015) were selected if they: were 18-63 years old; had an MS diagnosis; had newly initiated sc IFNβ-1a, dimethyl fumarate, fingolimod, or teriflunomide (first claim = index); had no evidence of DMD 12-months pre-index; and had 12-month eligibility pre- and post-index...
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30559975/updated-diagnostic-criteria-for-neuromyelitis-optica-spectrum-disorder-similar-outcomes-of-previously-separate-cohorts
#5
M McCreary, M A Mealy, D M Wingerchuk, M Levy, A DeSena, B M Greenberg
Background: The specificity of the aquaporin-4 antibody to predict recurrent inflammatory central nervous system disease has led to the design of the 2015 neuromyelitis optica spectrum disorder criteria which capture all aquaporin-4 antibody seropositive patients. Objective: The purpose of this study was to compare treatment outcomes in aquaporin-4 antibody seropositive patients who met the previous 2006 clinical criteria for neuromyelitis optica with patients who meet the 2015 neuromyelitis optica spectrum disorder criteria...
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30559974/self-report-sleep-quality-combined-with-sleep-time-variability-distinguishes-differences-in-fatigue-anxiety-and-depression-in-individuals-with-multiple-sclerosis-a-secondary-analysis
#6
Catherine F Siengsukon, Mohammed Alshehri, Mayis Aldughmi
Background: Nearly 70% of individuals with multiple sclerosis report sleep disturbances or poor sleep quality. Sleep disturbances may exacerbate or complicate the management of multiple sclerosis-related symptoms. While sleep variability has been associated with several health outcomes, it is unclear how sleep variability is associated with multiple sclerosis-related symptoms. Objective: The purpose of this study was to determine how total sleep time variability combined with self-reported sleep quality is associated with fatigue, depression, and anxiety in individuals with multiple sclerosis...
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30559973/monitoring-cognitive-change-in-multiple-sclerosis-using-a-computerized-cognitive-battery
#7
L De Meijer, D Merlo, O Skibina, E J Grobbee, J Gale, J Haartsen, P Maruff, D Darby, H Butzkueven, A Van der Walt
Background: Cognitive monitoring that can detect short-term change in multiple sclerosis is challenging. Computerized cognitive batteries such as the CogState Brief Battery can rapidly assess commonly affected cognitive domains. Objectives: The purpose of this study was to establish the acceptability and sensitivity of the CogState Brief Battery in multiple sclerosis patients compared to controls. We compared the sensitivity of the CogState Brief Battery to that of the Paced Auditory Serial Addition Test over 12 months...
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30559972/factors-associated-with-time-from-first-symptoms-to-diagnosis-and-treatment-initiation-of-multiple-sclerosis-in-switzerland
#8
Marco Kaufmann, Jens Kuhle, Milo A Puhan, Christian P Kamm, Andrew Chan, Anke Salmen, Jürg Kesselring, Pasquale Calabrese, Claudio Gobbi, Caroline Pot, Nina Steinemann, Stephanie Rodgers, Viktor von Wyl
Background: Recent studies emphasise the importance of timely diagnosis and early initiation of disease-modifying treatment in the long-term prognosis of multiple sclerosis. Objectives: The objective of this study was to investigate factors associated with extended time to diagnosis and time to disease-modifying treatment initiation in the Swiss Multiple Sclerosis Registry. Methods: We used retrospective data (diagnoses 1996-2017) of the survey-based Swiss Multiple Sclerosis Registry and fitted logistic regression models (extended time to diagnosis ≥2 years from first symptoms, extended time to disease-modifying treatment initiation ≥1 year from diagnosis) with demographic and a priori defined variables...
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30559971/successful-utilization-of-the-emr-in-a-multiple-sclerosis-clinic-to-support-quality-improvement-and-research-initiatives-at-the-point-of-care
#9
Kelly Claire Simon, Afif Hentati, Susan Rubin, Tiffani Franada, Darryck Maurer, Laura Hillman, Samuel Tideman, Monika Szela, Steven Meyers, Roberta Frigerio, Demetrius M Maraganore
Background: Many physicians enter data into the electronic medical record (EMR) as unstructured free text and not as discrete data, making it challenging to use for quality improvement or research initiatives. Objectives: The objective of this research paper was to develop and implement a structured clinical documentation support (SCDS) toolkit within the EMR to facilitate quality initiatives and practice-based research in a multiple sclerosis (MS) practice. Methods: We built customized EMR toolkits to capture standardized data at office visits...
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30515298/the-neutrophil-to-lymphocyte-ratio-is-associated-with-multiple-sclerosis
#10
I C Hasselbalch, H B Søndergaard, N Koch-Henriksen, A Olsson, H Ullum, F Sellebjerg, A B Oturai
Background: Subtypes of white blood cell counts are known biomarkers of systemic inflammation and a high neutrophil-to-lymphocyte ratio (NLR) has been associated with several autoimmune diseases. Few studies have investigated the NLR in multiple sclerosis (MS). Objective: To examine the association between NLR, MS and disability measured by the MS severity score (MSSS). Methods: Patients were included from the Danish Multiple Sclerosis Biobank...
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30505456/can-a-stress-management-programme-reduce-stress-and-improve-quality-of-life-in-people-diagnosed-with-multiple-sclerosis
#11
Susan Agland, Amanda Lydon, Sally Shaw, Rodney Lea, Sheila Mortimer-Jones, Jeannette Lechner-Scott
Background: Despite evidence of perceived stress as a risk factor for multiple sclerosis activity, the evidence for managing stress is limited.Objective To evaluate a stress management programme on perceived stress and quality of life, over 6 months. Methods: One hundred people with multiple sclerosis were randomly assigned to either a stress management programme of mindfulness, meditation and progressive muscle relaxation, or wait list. Perceived stress and quality of life were assessed at three intervals across 6 months...
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30349734/the-topographical-model-of-ms-empirical-evaluation-of-the-recapitulation-hypothesis
#12
Benjamin M Laitman, Karin Cook, Madhuri Fletcher, Stephen C Krieger
Objective: Using the topographical model of multiple sclerosis (MS) to evaluate a longitudinal cohort we (1) test the recapitulation hypothesis, positing that patients' "disease topography" predicts the clinical pattern of disability accumulation; and (2) identify leading indicators of progression. Methods: 10 patients who transitioned from relapsing-remitting MS to secondary progressive MS (SPMS) were evaluated. Neurologic exams were analyzed from relapses, at time of SPMS diagnosis, and most recent visit...
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30327724/corrigendum
#13
(no author information available yet)
[This corrects the article DOI: 10.1177/2055217318787826.].
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30327723/real-world-experience-of-fingolimod-in-patients-with-multiple-sclerosis-ms-fine-an-observational-study-in-the-uk
#14
Gordon Mazibrada, Charlotte Sharples, Ines Perfect
Background: Fingolimod is approved for the treatment of highly active relapsing-remitting multiple sclerosis in Europe. There is limited information on its effectiveness and safety in clinical practice within the UK. Objective: To evaluate retrospectively the effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis who were prescribed fingolimod by UK neurologists within the National Health Service. Methods: This was a multicentre, observational study conducted in the UK...
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30263146/the-effect-of-disease-modifying-therapies-on-cd62l-expression-in-multiple-sclerosis
#15
Margarete Maria Voortman, Paul Greiner, Daniel Moser, Martin Helmut Stradner, Winfried Graninger, Adrian Moser, Bernd Haditsch, Christian Enzinger, Siegrid Fuchs, Franz Fazekas, Johannes Fessler, Michael Khalil
Background: The increasing armamentarium of disease-modifying therapies in multiple sclerosis is accompanied by potentially severe adverse effects. The cell-adhesion molecule CD62L, which facilitates leukocyte extravasation, has been proposed as a predictive marker for treatment tolerability. However, pre-analytical procedures might impact test results, thereby limiting its clinical usability. Whether the immediate analysis of CD62L expression of peripheral blood mononuclear cells can aid treatment decision making is yet unclear...
July 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30186620/pain-in-aqp4-igg-positive-and-mog-igg-positive-neuromyelitis-optica-spectrum-disorders
#16
Susanna Asseyer, Felix Schmidt, Claudia Chien, Michael Scheel, Klemens Ruprecht, Judith Bellmann-Strobl, Alexander U Brandt, Friedemann Paul
Background: Pain is a frequent symptom in aquaporin-4-immunoglobulin-G-positive neuromyelitis optica spectrum disorders (AQP4-IgG-pos. NMOSD). Data on pain in myelin-oligodendrocyte-glycoprotein-immunoglobulin-G autoimmunity with a clinical NMOSD phenotype (MOG-IgG-pos. NMOSD) are scarce. Objective: The objective of this paper is to investigate pain in MOG-IgG-pos. NMOSD, AQP4-IgG-pos. NMOSD and NMOSD without AQP4/MOG-IgG detection (AQP4/MOG-IgG-neg. NMOSD). Methods: Forty-nine MOG-IgG-pos...
July 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30116550/reference-videos-reduce-variability-of-motor-dysfunction-assessments-in-multiple-sclerosis
#17
Marcus D'Souza, Saskia Steinheimer, Jonas Dorn, Cecily Morrison, Jacques Boisvert, Kristina Kravalis, Jessica Burggraaff, Caspar Ep van Munster, Manuela Diederich, Abigail Sellen, Christian P Kamm, Frank Dahlke, Bernard Mj Uitdehaag, Ludwig Kappos
Motor dysfunction, particularly ataxia, is one of the predominant clinical manifestations in patients with multiple sclerosis (MS). Assessment of motor dysfunction suffers from a high variability. We investigated whether the clinical rating of ataxia can be improved through the use of reference videos, covering the spectrum of severity degrees as defined in the Neurostatus-Expanded Disability Status Scale. Twenty-five neurologists participated. The variability of their assessments was significantly lower when reference videos were used (SD = 0...
July 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30116549/differences-in-clinical-features-between-optic-neuritis-in-neuromyelitis-optica-spectrum-disorders-and-in-multiple-sclerosis
#18
Jindapa Srikajon, Sasitorn Siritho, Chanon Ngamsombat, Naraporn Prayoonwiwat, Niphon Chirapapaisan
Background: Optic neuritis (ON) is one of the common manifestations both in neuromyelitis-optica spectrum disorders (NMOSD) and in multiple sclerosis (MS). Objectives: The objective of this paper is to compare clinical presentations, laboratories and imaging findings in ON associated with MS and NMOSD. Methods: A retrospective chart review was performed in patients presenting with ON in 59 NMOSD patients with 72 eyes' involvement and 163 ON attacks, and 20 MS patients with 23 eyes' involvement and 36 ON attacks...
July 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30094057/cerebrospinal-fluid-gap-43-in-early-multiple-sclerosis
#19
U Rot, Å Sandelius, A Emeršič, H Zetterberg, K Blennow
Background/Objective: Novel biomarkers identifying and predicting disease activity in multiple sclerosis (MS) would be valuable for primary diagnosis and as outcome measures for monitoring therapeutic effects in clinical trials. Axonal loss is present from the earliest stages of MS and correlates with disability measures. Growth-associated protein 43 (GAP-43) is a presynaptic protein with induced expression during axonal growth. We hypothesized this protein could serve as a biomarker of axonal regeneration capacity in MS...
July 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30090642/promotion-of-physical-activity-and-exercise-in-multiple-sclerosis-importance-of-behavioral-science-and-theory
#20
REVIEW
Robert W Motl, Dorothy Pekmezi, Brooks C Wingo
There is an obvious disconnect between evidence of benefits and rates of participation in exercise and physical activity among people living with multiple sclerosis (MS). We propose that the problem with exercise behavior in MS (i.e. lack of broad or increasing participation by people with MS despite evidence of meaningful benefits) might be ameliorated through the inclusion of behavior change theory in the design of exercise programs and promotion efforts, as has been undertaken in other populations such as breast cancer survivors...
July 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
journal
journal
52506
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"